Back

Low-dose rivaroxaban after left atrial appendage closure: The randomized ADRIFT study

2 September 2019 (09:24 - 09:42)
Organised by:
Congress Presentation Part of: Late Breaking Science in Intervention Anticoagulants ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Gilles Montalescot

Sorbonne University, Paris (France)

4 More presentations in this session

Presentation thumbnail
Immediate versus Delayed Stenting After Primary Percutaneous Reperfusion in ST-Elevation Myocardial Infarction: The PRIMACY Bayesian Randomized Controlled Trial
Doctor M. Jolicoeur (Montreal, CA)
Slides Video
Presentation thumbnail
Percutaneous left atrial appendage closure versus novel anticoagulation agents in high-risk atrial fibrillation patients (PRAGUE-17 study)
Doctor P. Osmancik (Prague, CZ)
Slides Video
Presentation thumbnail
Ultrathin-strut biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in acute myocardial infarction: a randomized controlled trial
Doctor J. Iglesias (Geneva, CH)
Slides Video
Presentation thumbnail
Randomized, Multicenter Comparison of Intensified versus Standard Loading Strategies with P2Y12-Receptor-Inhibitors in Patients Undergoing Elective PCI
Professor J. Mehilli (Landshut, DE)
Slides Video

Access the full session

Session thumbnail
Late Breaking Science in Intervention

The Event

Event poster

ESC Congress 2019

2 September 2019 09:24 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in atrial fibrillation: do not forget the left atrial appendage!
31 March 2025
thumbnail
Congress Presentation
Peridevice leak and device-related thrombus in the OPTION randomized trial
29 August 2025
thumbnail
Congress Session
Advances in left atrial appendage and patent foramen ovale closure
2 September 2024
thumbnail
Congress Presentation
Comparative efficacy and safety of antithrombotic regimens following left atrial appendage occlusion therapy in atrial fibrillation patients: a comprehensive Bayesian network meta-analysis
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources